NASDAQ:CRMD CorMedix Q2 2025 Earnings Report $8.23 -0.29 (-3.40%) Closing price 08/20/2026 04:00 PM EasternExtended Trading$8.22 -0.01 (-0.07%) As of 08:16 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast CorMedix EPS ResultsActual EPS$0.28Consensus EPS $0.20Beat/MissBeat by +$0.08One Year Ago EPS-$0.25CorMedix Revenue ResultsActual Revenue$39.74 millionExpected Revenue$29.88 millionBeat/MissBeat by +$9.86 millionYoY Revenue Growth+4,830.10%CorMedix Announcement DetailsQuarterQ2 2025Date8/7/2025TimeBefore Market OpensConference Call DateThursday, August 7, 2025Conference Call Time7:30AM ETConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) CorMedix Earnings HeadlinesCorMedix Inc. (CRMD) Stock Earnings Call Transcripts - Yahoo Finance1 hour ago | finance.yahoo.comCorMedix (CRMD) Q2 2026 Earnings Call TranscriptAugust 20 at 1:09 PM | finance.yahoo.comSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from collapsing — and billionaire Sam Altman is now an investor. This under-the-radar firm is drawing serious attention from those watching the energy infrastructure space closely.August 21 at 1:00 AM | Altimetry (Ad)What is HC Wainwright's Forecast for CorMedix Q3 Earnings?August 20 at 1:29 AM | americanbankingnews.comCorMedix (NASDAQ:CRMD) Stock Price Up 7.3% Following Analyst UpgradeAugust 19 at 1:52 AM | americanbankingnews.comCorMedix: Durable Commercial Base, But 2027 Is The Real TestAugust 18 at 5:23 AM | seekingalpha.comSee More CorMedix Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like CorMedix? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CorMedix and other key companies, straight to your email. Email Address About CorMedixCorMedix (NASDAQ:CRMD). is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to reduce inflammation and prevent infection in critically and chronically ill patient populations. The company’s lead product candidate, Neutrolin, is a catheter lock solution that combines taurolidine, heparin and citrate to prevent catheter-related bloodstream infections (CRBSIs) in patients undergoing hemodialysis. Neutrolin has received market authorization in the European Union under the CE Mark and is positioned to address a significant unmet medical need for infection prevention in dialysis centers. In addition to its lead asset, CorMedix is advancing a biochemical portfolio aimed at mitigating complications associated with peritoneal dialysis and other high-risk procedures. The company is engaged in clinical and regulatory activities designed to support product labeling updates and broader patient access. Collaborative partnerships with dialysis providers and distributors help position CorMedix to deliver its therapies into established treatment settings. Founded in the mid-2000s and headquartered in Piscataway, New Jersey, CorMedix operates with a lean corporate structure that leverages external manufacturing and distribution networks. The company’s senior management team is led by President and Chief Executive Officer Craig Fraser, who brings more than 30 years of experience in the biopharmaceutical industry. CorMedix continues to pursue regulatory milestones and commercial arrangements that aim to expand its reach across North America, Europe and select emerging markets.View CorMedix ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Walmart's Post-Earnings Drop Could Be a Buying Opportunity3 Energy Stocks Raising Dividends as the Sector Surges5 Reasons the S&P 500 Could Keep Rallying Through Year-EndSociedad Química y Minera’s Lithium Boom Is Back, But Iodine Steals the ShowNasdaq’s 23-Hour Trading Push Could Turn Global Liquidity Into a Growth EngineForget Chips: These 3 Stocks Are Building the AI Data Center BoomAnalog Devices’ AI Pivot Could Push Shares to Fresh Highs Upcoming Earnings PDD (8/24/2026)Bank Of Montreal (8/25/2026)Bank of Nova Scotia (8/25/2026)Heico (8/25/2026)Intuit (8/25/2026)Salesforce (8/26/2026)CrowdStrike (8/26/2026)NVIDIA (8/26/2026)Synopsys (8/26/2026)Canadian Imperial Bank of Commerce (8/27/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
